Australia 'Missing Out' On Pharma Exports to Asian Growth Markets
This article was originally published in Scrip
Australia stands to miss out on opportunities to increase pharmaceutical exports to the burgeoning Asian markets unless the government takes the necessary steps to boost the biopharmaceutical sector and encourage investment in R&D and high-tech manufacturing, says the industry group Medicines Australia.
You may also be interested in...
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.
The UK government has awarded “urgent public health status” to a clinical trial program that will test one investigational product and four existing drugs in an effort to quickly find new treatments for patients hospitalized with serious COVID-19 infection.